BROWSE·page 221 of 1397

Browse EX-10 agreements

16,757 total material contract exhibits.


EX-10.26

FullPAC, Inc.

** **

Exhibit 10.26

** **

THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

** **

SECURED PROMISSORY NOTE

September 15, 2026

** **

…

EX-10.26·S-1/A·CIK 2076148·ACC 0001493152-26-043417·Filed Sep 18, 2026, 17:30 ET

EX-10.29

FullPAC, Inc.

PROMISSORY NOTE

U.S. $75,000 Issuance Date: July 24, 2026

The undersigned maker (“Maker”) promises to pay to the order of Travis Trawick (the “Lender”) the principal sum of U.S. $75,000.00.

On December 31, 2026, all outstanding principal shall be immediately due and payable in full.

Any default by Maker in the payment of principal under this Note shall constitute an event of default hereunder. Venue of any litigation arising in connection with this Note shall be in Virginia Beach, Virginia.

…

EX-10.29·S-1/A·CIK 2076148·ACC 0001493152-26-043417·Filed Sep 18, 2026, 17:30 ET

EX-10.30

FullPAC, Inc.

PRISTINE CAPITAL PARTNERS

** **

SALES-BASED FINANCING DISCLOSURE FORM

PRISTINE CAPITAL PARTNERS LLC 2361 Nostrand Ave, Brooklyn, NY 11210 (786) 349-3807 | info@pristinecapitalpartners.com

| | | |

…

EX-10.30·S-1/A·CIK 2076148·ACC 0001493152-26-043417·Filed Sep 18, 2026, 17:30 ET

EXHIBIT 10.1

VisionWave Holdings, Inc.

AT-THE-MARKET ISSUANCE SALES AGREEMENT

** **

September 18, 2026

Aegis Capital Corp.

1345 Avenue of the Americas, 27th Floor

New York, NY 10105

Ladies and Gentlemen:

VisionWave Holdings, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Aegis Capital Corp. (“Sales Agent”), as follows:

| | | |

…

EX-10.1·8-K·CIK 2038439·ACC 0001731122-26-001264·Filed Sep 18, 2026, 17:30 ET

EX-10.1

CREDIT ACCEPTANCE CORP

CONSUMER PROTECTION DIVISION, OFFICE OF THE ATTORNEY GENERAL OF MARYLAND,        

    Plaintiff,                         

v.                                

CREDIT ACCEPTANCE CORPORATION,        

    Defendant.                    

IN THE CIRCUIT COURT FOR HOWARD COUNTY        

Case No. __________________    

*    *    *    *    *    *    *    *    *    *    *    *    

FINAL JUDGMENT AND CONSENT DECREE

Plaintiff, the Consumer Protection Division of the Office of the Attorney General of Maryland (the “Division” or “Plaintiff”)1has brought this action pursuant to the provisions of the Maryland Consumer Protection Act, Md. Code Ann., Com. Law §§ 13-101 through 13-501 (2013 Repl. Vol. and 2025 Supp.) (the “Maryland Consumer Protection Act”) having filed a Complaint against Defendant Credit Acceptance Corporation (“Defendant” or “CAC”, and together with Plaintiff, the “Parties”).

…

EX-10.1·8-K·CIK 885550·ACC 0000885550-26-000192·Filed Sep 18, 2026, 17:29 ET

EX-10.1

BCB BANCORP INC

**BCB BANCORP, INC. **

**11,000,000 Shares of Common Stock **

**No Par Value Per Share **

***Underwriting Agreement ***

**September 16, 2026 **

PIPER SANDLER & CO.

1251 Avenue of the Americas, 6th Floor

New York, New York 10022

Ladies and Gentlemen:

BCB Bancorp, Inc., a New Jersey corporation (the “Company”), the holding company for BCB Community Bank (the “Bank”), confirms its agreement with Piper Sandler & Co. (the “Underwriter”), subject to the terms and conditions stated herein, with respect to (i) the issuance and sale by the Company and the purchase by the Underwriter of 11,000,000 shares of the Company’s common stock, no par value per share (the “Initial Shares”); and (ii) the grant by the Company to the Underwriter of the option described in Section*** 2(b)* hereof to purchase all or any part of 1,650,000 additional shares of the Company’s common stock (the “Option Shares” and, together with the Initial Shares, the “Shares”). The Company understands that the Underwriter proposes to make a public offering of the Shares as soon as the Underwriter deems ad

…

EX-10.1·8-K·CIK 1228454·ACC 0001193125-26-395743·Filed Sep 18, 2026, 17:28 ET

FIRST AMENDMENT

TO

LEASE AGREEMENT

This First Amendment to the Lease Agreement (the “Lease”), dated October 15, 2023, by and between G&A Real Estate Investment Group LLC as the "Landlord" and Veriheal Inc. hereinafter known as the "Tenant" is made effective as of: August 28, 2025 (the “First Amendment”).

Landlord and Tenant Agree to the amend the Lease as follows:

1. Lease Term shall read:

…

EX-10.5·S-1/A·CIK 2078149·ACC 0001096906-26-001390·Filed Sep 18, 2026, 17:28 ET

VERI MEDTECH HOLDINGS, INC.
STOCK INCENTIVE 2025 PLAN
AMENDED AND RESTATED EFFECTIVE AS OF SEPTEMBER 12, 2026

The name of the plan is the Veri Medtech Holdings, Inc. Stock Incentive 2025 Plan, as amended and restated effective as of September 12, 2026 (the “2025 Plan”). The 2025 Plan was originally effective as of September 30, 2025 and is hereby amended and restated in its entirety effective as of September 12, 2026 (the “Amendment and Restatement Date”).

…

EX-10.6·S-1/A·CIK 2078149·ACC 0001096906-26-001390·Filed Sep 18, 2026, 17:28 ET

STOCK REPURCHASE PLAN

Veri MedTech Holdings, Inc.

202**6 STOCK REPURCHASE PLAN**

VERI MEDTECH HOLDINGS, INC.

JU**LY 15, 202**6

Stock Repurchase Program**: ** The 2026 Program authorizes the Company to repurchase, at any time, up to 3,000,000 shares of its VRHI common stock on the open market, in privately negotiated transactions or otherwise at the Company’s sole discretion.  The 2026 Program may be altered, suspended, or terminated at any time based on various factors including but not limited to market conditions, share price, alternative investment opportunities. The 2026 Program does not obligate or mandate the Company to make any stock purchases of any specific amount, supersedes any other program(s) and continues until terminated.

EX-10.7·S-1/A·CIK 2078149·ACC 0001096906-26-001390·Filed Sep 18, 2026, 17:28 ET

FORM OF CONSULTING AGREEMENT

Veri MedTech Holdings, Inc.

**CONFIDENTIAL **

CONSULTING AGREEMENT

This Consultant Agreement (“Agreement”) is made and entered into as of the last date of signature below by and between **____________________ **(the “Consultant and **Veri Medtech Holdings, Inc. and its affiliates **(the “Client,”).

In consideration for mutual promises and covenants made herein, the undersigned parties agree to as follows:

1. Engagement.** **The Client agrees to engage Consultant as an independent Consultant to perform the duties outlined herein. (see **Section 2 **below). This Agreement shall be for a period of four (4) years; and continue from year-to-year thereafter unless otherwise agreed to by the parties at the end of the then current term.

2. Duties & Services. Consultant agrees to provide services to the Client follows:

_______________________________________________________________

…

EX-10.3·S-1/A·CIK 2078149·ACC 0001096906-26-001390·Filed Sep 18, 2026, 17:28 ET

INDEPENDENT DIRECTOR AGREEMENT

This DIRECTOR AGREEMENT (the “Agreement”) is made and entered into as of this [ ] day of [ ], by and between VERI MEDTECH HOLDINGS, INC., a Delaware corporation (the “Company”), and [ ] (the “Independent Director”) and shall become effective on the closing date of the Company’s initial public offering (the “Effective Date”).

WHEREAS, the Company desires to engage the Independent Director, and the Independent Director desires to serve, as a non-employee director of the Company, subject to the terms and conditions contained in this Agreement.

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, the receipt of which is hereby acknowledged, the Company and the Independent Director, intending to be legally bound, hereby agree as follows:

1. DEFINITIONS.

(a) “Corporate Status” describes the capacity of the Independent Director with respect to the Company and the services performed by the Independent Director in that capacity.

…

EX-10.2·S-1/A·CIK 2078149·ACC 0001096906-26-001390·Filed Sep 18, 2026, 17:28 ET